U.S. Serial No. 10/092,088 Attorney Docket No. P-022-RC1 Page 2 of 6

## II. AMENDMENTS TO THE CLAIMS

- 1-71. (Canceled)
- 72. (Currently Amended) A compound of formula II:

Ħ

wherein

-R<sup>21</sup> is a group of the formula:

U.S. Serial No. 10/092,088 Attorney Docket No. P-022-RC1 Page 3 of 6

$$R^{16}$$
,  $R^{26}$   $R^{26}$   $R^{26}$   $R^{26}$   $R^{26}$   $R^{27}$   $R^{27}$ 

wherein

R<sup>15</sup> is -R<sup>0</sup>-Y-R<sup>b</sup>-(Z),

R<sup>16</sup> is hydrogen or methyl;

R<sup>22</sup> is -OH;

R<sup>23</sup> is hydrogen;

R<sup>24</sup> is hydrogen;

R<sup>25</sup>-is-isobutyl;

R<sup>26</sup> is hydrogen or methyl;

R<sup>27</sup> is hydrogen or -CH<sub>2</sub>COOH;

R<sup>a</sup> is -CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-;

R<sup>b</sup> is alkylene having from 8 to 12 carbon atoms;

U.S. Serial No. 10/092,088 Attorney Docket No. P-022-RC1 Page 4 of 6

Y-is-NH-;
Z is hydrogen
n-is1;
x is 1;
and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof.

- 73. (Previously Presented) The compound of Claim 72, wherein R<sup>16</sup> is methyl
- 74. (Previously Presented) The compound of Claim 72, wherein R<sup>26</sup> is methyl
- 75. (Previously Presented) The compound of Claim 72, wherein R<sup>27</sup> is hydrogen.
- 76. (Previously Presented) The compound of Claim 72, wherein R<sup>a</sup> is -CH<sub>2</sub>CH<sub>2</sub>-.
- 77. (Currently Amended) The compound of Claim 72, wherein  $\mathbb{R}^b$  and  $\mathbb{Z}$  form  $\mathbb{R}^b$ -H is an n-octyl, n-nonyl, n-decyl, n-undecyl or n-dodecyl group.
- 78. (Currently Amended) The compound of Claim 72, wherein  $\mathbb{R}^{b}$  and Z form  $\mathbb{R}^{b}$ -H is an *n*-decyl group.
- 79. (Previously Presented) The compound of Claim 72, wherein R<sup>15</sup> is -CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>10</sub>-H.
- 80. (Previously Presented) A pharmaceutical composition comprising a compound of any of Claims 72-79 and a pharmaceutically acceptable carrier.
- 81. (Previously Presented) A method of inhibiting the growth of bacteria in a mammal infected with or exposed to bacteria, the method comprising administering to the mammal a composition according to Claim 80 for a time and under conditions effective to inhibit growth of bacteria.